Has Saba Assar, MD received payments from drug or device companies?

Yes. Drug and device makers reported $47,470 in general payments to Saba Assar, MD across 168 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Saba Assar, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Saba Assar, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Saba Assar, MD

Cardiovascular Disease · New York, NYNPI 1730575275

Payments from drug & device makers

What this record shows

This record is dominated by grants: $33,000 of the $47,470 with a category attached, or 69.5%. Boston Scientific accounts for 60.9% of it on its own, with 26 other manufacturers making up the rest. Reporting peaked in 2023 at $28,422 and has fallen 82.8% since, to $4,901 in 2025. Among cardiovascular disease clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$47,470in general payments, 2019–2025

Across 168 payments — averaging $282.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Boston Scientific$29K
Medtronic$10K
Abbott$4K
Abiomed$1K
Shockwave Medical, Inc$640
AstraZeneca$345
plus $3K from 21 others

What the payments were for

Grants$33,00070%
Travel & lodging$5,27511%
Food & beverage$8,85019%
Education$3451%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Boston Scientific	47	$28,905
Medtronic	20	$9,795
Abbott	28	$3,877
Abiomed	14	$1,215
Shockwave Medical, Inc	4	$640
AstraZeneca	6	$345
Cardiovascular Systems Inc.	4	$332
Stryker	4	$269
Cardiva Medical, Inc.	3	$226
Verge Medical, Inc.	2	$216
Amgen	6	$211
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)	3	$203
Chiesi USA, Inc.	4	$183
Heartflow, Inc.	1	$182
Teleflex LLC	1	$140
Penumbra, Inc.	1	$139
Edwards Lifesciences	1	$118
Terumo Medical Corporation	1	$114
Asahi Intecc USA, Inc.	6	$77
Boehringer Ingelheim	4	$61
Philips North America LLC	1	$45
E.r. Squibb & Sons, L.L.C.	2	$43
Acist Medical Systems, Inc.	1	$40
Biotronik Inc.	1	$35
Johnson & Johnson	1	$20
Ironshore Pharmaceuticals Inc.	1	$20
Novartis	1	$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

RESOLUTE ONYX$8,140
DRAGONFLY OPSTAR$1,714
OPTIS$1,472
GENERAL - THERAPIES$1,156
Impella$730
ONYX FRONTIER$673
AVVIGO Guidance System$654
Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$543
Diamondback Coronary$291
Resolute$280
FLASH Ostial System$216
Cardiva VASCADE 5F VCS$200
FFRct$182
GENERAL VASCULAR ACCESS$171
ROTAPRO$169
COROFLOW$158
FFRangio$146
TURNPIKE$140
Indigo System$139
KENGREAL$132

How this compares

$47,470 in reported general payments places this provider in the 90th percentile of 2,302 cardiovascular disease providers in New York.

See all cardiovascular disease providers in New York →

Medicare billing

Part B allowed, 2024

$87,105

Medicare patients

183

Services billed

543

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
EliquisApixaban	11	$10,586
Metoprolol Succinate	18	$376
Atorvastatin Calcium	37	$364
ClopidogrelClopidogrel Bisulfate	26	$253
Amlodipine Besylate	22	$192
Losartan Potassium	18	$149
Isosorbide Mononitrate ErIsosorbide Mononitrate	17	$117
Carvedilol	12	$103

Paid to pharmacies, not to this prescriber.

Other cardiovascular disease in New York

Roger HajjarNew York$5.2M
Gregg StoneNew York$2M
Philippe GenereuxNew York$1.3M
Adam RosenbluthNew York$1.1M
Megha PrasadNew York$813K
Eyal HerzogNew York$645K
Nisha JhalaniNew York$443K
Roxana MehranNew York$432K
Howard WeintraubNew York$328K
Anuradha Lala-TrindadeNew York$324K

See the full list for New York →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →